Sarcoma  >>  Imfinzi (durvalumab)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

7 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Imfinzi (durvalumab) / AstraZeneca
NCT02890368: Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides

Checkmark For advanced relapsed/refractory hematologic malignancies
Jan 2020 - Jan 2020: For advanced relapsed/refractory hematologic malignancies
Hourglass Oct 2019 - Dec 2019 : For CTCL patients on continuation therapy
Checkmark Updated data for CTCL at ASH 2018 [screenshot]
Dec 2018 - Dec 2018: Updated data for CTCL at ASH 2018 [screenshot]
More
Terminated
1
56
US
TTI-621 Monotherapy, SIRPα-IgG1 Fc, TTI-621 + PD-1/PD-L1 Inhibitor, SIRPα-IgG1 Fc + PD-1/PD-L1 Inhibitor, TTI-621 + pegylated interferon-α2a, SIRPα-IgG1 Fc + pegylated interferon-α2a, TTI-621 + T-Vec, SIRPα-IgG1 Fc + talimogene laherparepvec, TTI-621 + radiation, SIRPα-IgG1 Fc + radiation
Pfizer
Solid Tumors, Mycosis Fungoides, Melanoma, Merkel-cell Carcinoma, Squamous Cell Carcinoma, Breast Carcinoma, Human Papillomavirus-Related Malignant Neoplasm, Soft Tissue Sarcoma
03/20
03/20
TRAMUNE, NCT03085225: Trabectedin Combined With Durvalumab in Patients With Advanced Pretreated Soft-tissue Sarcomas and Ovarian Carcinomas.

Checkmark From TRAMUNE trial in combination with trabectedin in locally advanced/unresectable soft-tissue sarcoma at ESMO 2020
Sep 2020 - Sep 2020: From TRAMUNE trial in combination with trabectedin in locally advanced/unresectable soft-tissue sarcoma at ESMO 2020
Completed
1
40
Europe
Combination of trabectedin with durvalumab
Institut Bergonié, AstraZeneca, PharmaMar
Ovarian Carcinoma, Soft Tissue Sarcoma
11/20
01/22
NCT03056599: Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma

Completed
1
23
US
Multiple drug microinjection, Doxorubicin, Docetaxel, Gemcitabine, Interferon gamma, Pembrolizumab, Ipilimumab, Interferon alfa-2B, Bortezomib, Aldesleukin, Trabectedin, Eribulin, Olaratumab, Atezolizumab, Durvalumab, Avelumab, Nivolumab, Larotrectinib, Entrectinib, Avapritinib, Saline, CIVO device
Presage Biosciences, Fred Hutchinson Cancer Center, University of Washington, Northwell Health, Oregon Health and Science University
Soft Tissue Sarcoma Adult
07/21
09/21
NCT04521686: Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations

Active, not recruiting
1
200
Europe, Japan, US, RoW
LY3410738, Gemcitabine, LY188011, Cisplatin, Durvalumab
Eli Lilly and Company, Loxo Oncology, Inc.
Cholangiocarcinoma, Chondrosarcoma, Glioma, Any Solid Tumor
07/23
05/25
SADDRIN-1, NCT05116254 / 2021-000042-17: Sarcomas and DDR-Inhibition; a Combined Modality Study

Recruiting
1
30
Europe
AZD1390 + radiotherapy, AZD1390 + durvlaumab + radiotherapy
The Netherlands Cancer Institute, Leiden University Medical Center, University Medical Center Nijmegen
Soft Tissue Sarcoma Adult
03/26
07/28
RESOLVE, NCT05154994: Tremelimumab + Durvalumab(MEDI4736)+ Belinostat in ARID1A Mutated Cancer Focus on Urothelial Carcinoma

Suspended
1
9
US
Belinostat, Beleodaq, PXD 101, PXD101, Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI-4736, MEDI4736
University of Utah, National Cancer Institute (NCI)
Infiltrating Urothelial Carcinoma, Sarcomatoid Variant, Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Unresectable Urothelial Carcinoma
11/24
11/26
NCT02812420: Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery

Active, not recruiting
1
54
US
Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI-4736, MEDI4736, Therapeutic Conventional Surgery, Tremelimumab, Anti-CTLA4 Human Monoclonal Antibody CP-675,206, CP-675, CP-675,206, CP-675206, Ticilimumab
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Hydronephrosis, Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant, Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant, Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant, Infiltrating Renal Pelvis Urothelial Carcinoma, Sarcomatoid Variant, Renal Pelvis Urothelial Carcinoma, Stage II Bladder Urothelial Carcinoma AJCC v6 and v7, Stage II Renal Pelvis Cancer AJCC v7, Stage II Ureter Cancer AJCC v7, Stage II Urethral Cancer AJCC v7, Stage III Bladder Urothelial Carcinoma AJCC v6 and v7, Stage III Renal Pelvis Cancer AJCC v7, Stage III Ureter Cancer AJCC v7, Stage III Urethral Cancer AJCC v7, Stage IV Renal Pelvis Cancer AJCC v7, Stage IV Ureter Cancer AJCC v7, Stage IV Urethral Cancer AJCC v7, Ureter Urothelial Carcinoma, Urethral Urothelial Carcinoma
12/24
12/24

Download Options